论文部分内容阅读
目的观察别嘌醇对应用华法林抗凝治疗的房颤合并高尿酸血症患者凝血酶原时间的国际标准化比值(INR)的影响。方法收集华法林抗栓治疗的慢性永久性房颤合并高尿酸血症患者240例,随机分为两组。华法林治疗组(120例)维持原剂量华法林抗凝治疗,嘱低嘌呤饮食;联合治疗组(120例)在常规华法林抗栓治疗,低嘌呤饮食的基础上,加用别嘌醇100 mg,每日3次口服。治疗2周后,观察并检测两组患者治疗前后INR的变化。结果联合治疗组的INR较华法林治疗组明显增高(P<0.05)。结论别嘌醇会增加华法林的抗栓作用,治疗过程中应定期监测INR,及时调整华法林用量。
Objective To investigate the effect of allopurinol on the international normalized ratio (INR) of prothrombin time in patients with atrial fibrillation and hyperuricemia treated with anticoagulation with warfarin. Methods A total of 240 patients with chronic permanent atrial fibrillation and hyperuricemia who were treated with warfarin antithrombotic therapy were randomly divided into two groups. Warfarin treatment group (120 cases) to maintain the original dose of warfarin anticoagulant therapy, hypoglycemic diet; combination therapy group (120 cases) in the conventional warfarin antithrombotic therapy, low purine diet, plus allopurinol 100 mg , 3 times a day orally. After 2 weeks of treatment, the changes of INR before and after treatment were observed and detected in both groups. Results The INR of combination therapy group was significantly higher than warfarin treatment group (P <0.05). Conclusion Allopurinol will increase the antithrombotic effect of warfarin. During the treatment, INR should be monitored regularly to adjust the dosage of warfarin.